Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8350+0.0548 (+7.02%)
At close: 04:00PM EDT
0.8350 0.00 (0.00%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7802
Open0.7700
Bid0.0000 x 800
Ask0.0000 x 800
Day's range0.7700 - 0.8500
52-week range0.6700 - 4.7800
Volume209,804
Avg. volume2,256,995
Market cap6.823M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-2.1720
Earnings date19 Sept 2022 - 23 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.00
  • Simply Wall St.

    Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected

    The recent 11% drop in Benitec Biopharma Inc.'s ( NASDAQ:BNTC ) stock could come as a blow to insiders who purchased...

  • GlobeNewswire

    Benitec Biopharma Releases Q3 2022 Financial Results

    HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exch

  • PR Newswire

    Benitec Biopharma Discloses Q2 2022 Financial Results

    Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q2 ended December 31, 2021. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2021, with the U.S. Securities and Exchange Commission.